Telangana's life sciences bet: ₹73,000 crore and 14,000 acres

By Srinath · 7 August 2026

Hyderabad's public identity is technology. Its more durable industrial advantage may be pharmaceuticals.

Over the last two years, Telangana's life sciences sector has attracted more than ₹73,000 crore in investment. That is not a projection or a memorandum total — it is committed capital across a sector that was already the largest of its kind in India.

The numbers

Why this is a stronger position than the IT story

Not because it is bigger. It is not. But it is harder to move.

An IT services centre or even a GCC can, in principle, be relocated. The people are portable, the equipment is generic, and the decision sits with a corporate committee weighing costs across several countries.

A pharmaceutical manufacturing plant cannot. It is a physical asset built to a specific regulatory specification, inspected and approved by the US FDA and its equivalents, with a supply chain and a trained workforce built around it. Relocating means re-qualifying the site with every regulator that matters — a multi-year, multi-hundred-crore exercise nobody undertakes for a modest cost saving.

That is what an industrial moat looks like. Hyderabad has spent thirty years building one, and the compounding is now visible in who is choosing to expand here.

The names matter more than the totals

Eli Lilly at ₹8,850 crore and Sanofi at ₹3,600 crore are not cost-arbitrage decisions. These are companies with global manufacturing options choosing Hyderabad for capacity, and their diligence processes are unforgiving. Each such commitment makes the next one easier, because the ecosystem — specialist suppliers, regulatory expertise, trained chemists — deepens with every arrival.

Genome Valley's 200-plus companies across roughly 2,000 acres is that compounding made physical. The fourth phase adds another 100-plus acres.

What it means for a business here

Very few readers will build a pharma plant. The relevant effects are downstream.

The 14,000-acre Pharma City is a land story before it is a pharma story. Developments of that scale require housing, services, schooling, logistics and retail within commuting distance, and those requirements arrive years before the plants reach full capacity.

It diversifies the city's employment base. A Hyderabad dependent on IT alone is exposed to one global cycle. A Hyderabad with pharma manufacturing, biotech R&D and GCCs is considerably more resilient — and resilience is what makes a property market survive a downturn rather than crater in one.

It creates a different customer. Manufacturing and R&D employment has a different geographic footprint from IT: it clusters around Genome Valley in the north and Pharma City in the south, not the western corridor everyone builds for.

The caveats

Announced investment and deployed investment are different quantities, and the gap between them in Indian industrial policy is habitually wide. The ₹73,000 crore figure is commitments; treat deployment as a separate question.

Hyderabad Pharma City at 14,000 acres has been in development for years and has faced environmental clearance and land acquisition challenges along the way. The 2030 targets of $25 billion and 500,000 jobs are ambitions published by the promoting body, not forecasts from a neutral party.

The underlying strength is real and verifiable in the companies that have actually built here. The round numbers attached to the future are aspirations. Both are worth knowing, and it is worth knowing which is which.